Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLCAR19: Obe-cel in B-cell Malignancies
NCT02935257Phase 1Active, not recruiting
- Sponsor
- University College London
- Start
- Sep 2017
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of obecabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and 3 more (5 arms), sponsored by University College London. Primary endpoints: Incidence of grade 3-5 toxicity causally related to the ATIMP at 28 days and Feasibility of manufacturing CD19CAR T-cells at 30 days. Started Sep 2017; status: active, not recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02935257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935257.